Research programme: ophthalmology therapeutics - Lees Pharmaceutical Holdings

Drug Profile

Research programme: ophthalmology therapeutics - Lees Pharmaceutical Holdings

Alternative Names: ZK-009

Latest Information Update: 15 Oct 2015

Price : $50

At a glance

  • Originator Lees Pharmaceutical Holdings; Unknown
  • Developer Lees Pharmaceutical Holdings
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top